Drug news
NICE in draft guidance recommends Remsima and Inflectra biosimilars for RA- Napp Pharma +Hospira
The National Institute of Care and Health Excellence (NICE) in draft guidance has recommended Remsima from Napp Pharma and Inflectra from Hospira both infliximab biosimilars for the treatment of Rheumatoid Arthritis in preference to the originator drug Remicade (infliximab) from Merck Inc. on grounds of cost. Remicade costs �419 per 100 ml vial and the biosimilars cost �377 per 100 ml vial.These discounts are modest compared to the 70% discount offered for the biosimilar by Orion Oy in Norway.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins